» Download Public Reports
About 200 reports
- Company report
- November 2012
- 4 pages
... Increased clinical costs associated with the lor-253 phase i clinical trial as well as spending on our il-17e program initiated in the current year. The increase in research and development expenditures ...
November 2012
... From country to country, and the time may be longer or shorter than that required for fda approval. The requirements governing the conduct of clinical trials, product licensing, pricing ...
October 2012
... Citoxlab group announces a 34 per cent revenue increase for the first half of 2012 one year after merger of france-based pre-clinical research organization, cit, and canada S lab ...
October 2012
... Clinical and regulatory expertise by developing new drug cands that can be used, either alone, or in combination with other drugs, to successfully manage cancer. The company also has expertise ...
December 2012
... As soon as practicable once financing is in place. There are no assurances that we will obtain the financing necessary to allow us to implement this aspect of our business plan, or to enter clinical trials ...
January 2013
... In this group would typically have one novel therapeutic product in clinical trials which would account for most of its value and its large cash burn. Since the average industry success rate is only one novel ...
December 2012
... To the 2012 year principally resulted from an increase of $22.8 Million in contract research organization and other clinical trial expenses, including consulting, and an increase of $2.1 Million for personnel ...
April 2013
... Of additional quantities of lor-253, increased clinical costs associated with the lor-253 phase i clinical trial as well as spending on our il-17e and lor-500 programs initiated and escalated in the current ...
February 2013
... Investigators, cover cost of patient care in clinical trials iom recommendations 2 key excerpt from the iom report The committee concluded that a robust, standing cancer clinical trials network ...
» Purchase Premium Reports
(From $ 250 - $ 250)
31 reports
March 2013
$ 250
Summary Zalicus Inc. (Zalicus) is a bio pharmaceutical company synergistic combination of drugs with a focus on the novel treatment of pain and inflammation conditions. Its portfolio comprises several ...
March 2013
$ 250
Summary Critical Outcome Technologies Inc. (COTI) is a pharmaceutical company, based in Canada. The company develops and discovers drug, optimization and pre-clinical development using a series of compute ...
April 2013
$ 250
Summary Algorithme Pharma Inc. (Algorithme Pharma), an operating company of Altasciences Company Inc., is a contract research organization. It offers early stage clinical research and drug development ...
